Clinical Trial Update: AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of selumetinib (AZD6244) in patients with recurrent or refractory multiple myeloma has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-08-19